Anti-TNFα therapy in inflammatory lung diseases

被引：206

作者：

Malaviya, Rama ^{[1
]}

Laskin, Jeffrey D. ^{[2
]}

Laskin, Debra L. ^{[1
]}

机构：

[1] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA

[2] Rutgers State Univ, Sch Publ Hlth, Dept Environm & Occupat Hlth, Piscataway, NJ 08854 USA

来源：

PHARMACOLOGY & THERAPEUTICS | 2017年 / 180卷

基金：

美国国家卫生研究院;

关键词：

TNF; Pulmonary disease; Lung injury; Biologics; Inflammation; TUMOR-NECROSIS-FACTOR; IDIOPATHIC PULMONARY-FIBROSIS; RESPIRATORY-DISTRESS-SYNDROME; PLACEBO-CONTROLLED TRIAL; BRONCHIAL EPITHELIAL-CELLS; RECEPTOR FUSION PROTEIN; FACTOR-KAPPA-B; ALVEOLAR MACROPHAGES; DOUBLE-BLIND; MONOCLONAL-ANTIBODY;

D O I：

10.1016/j.pharmthera.2017.06.008

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Increased levels of tumor necrosis factor (TNF) alpha have been linked to a number of pulmonary inflammatory diseases including asthma, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), sarcoidosis, and interstitial pulmonary fibrosis (IPF). TNF alpha plays multiple roles in disease pathology by inducing an accumulation of inflammatory cells, stimulating the generation of inflammatory mediators, and causing oxidative and nitrosative stress, airway hyperresponsiveness and tissue remodeling. TNF alpha-targeting biologics, therefore, present a potentially highly efficacious treatment option. This review summarizes current knowledge on the role of TNFa in pulmonary disease pathologies, with a focus on the therapeutic potential of TNF alpha-targeting agents in treating inflammatory lung diseases. (C) 2017 Elsevier Inc. All rights reserved.

引用

页码：90 / 98

页数：9

共 181 条

[31] Treatment of therapy-resistant sarcoidosis with adalimumab [J].